Adverse Event Label Expansion for GLP-1 Medications Due toOff-Label Use: Regulatory Implications and Challenges

The high-velocity growth of off-label administration of glucagon-like peptide-1 (GLP-1) receptor ‎agonists that were initially approved to be used as Type 2 diabetes medications has raised new ‎safety issues and initiated regulatory procedures for developing adverse event label expansions. ‎Since these agents are becoming popular in weight reduction, the treated population has become ‎less homogenous, and therefore, the risk of adverse events that were not seen during the pre-‎approval trials is more probable. The paper critically evaluates the pharmacological justification of ‎off-label use, the role of post-marketing surveillance in identifying safety signals, and the ‎regulatory frameworks of various jurisdictions regarding the correction of the labeling of that ‎product. It also deals with regulatory communication obligations of regulators, manufacturers, and ‎prescribers to communicate changing risks; and with operational impediments to the successful ‎implementation of label changes in a timely and consistent manner. It outlines the evidential ‎challenges in demonstrating causality among various patient groups as well as recommending ‎approaches to future regulation, including the development of dynamic labeling systems, ‎streamlined global pharmacovigilance, and enhanced safety research. Analysis indicates that the ‎adaptive, coordinated, and evidence-based strategies are essential to ensure the protection of public ‎health and, at the same time, maintain access to therapeutics in the new reality of changing ‎prescription patterns at a blistering pace.‎